{"DataElement":{"publicId":"3287969","version":"1","preferredName":"Stage Prognostic Factor Collaborative Staging Prior To Therapeutic Procedure Neoplasm Size Code","preferredDefinition":"The CS pre-treatment data items include all information prior to the start of therapy.  In rare circumstances where workup could not be completed prior to therapy, these items may be based on testing after limited treatment in the absence of progression or regression of disease such as delayed planned or usual diagnostic workup.","longName":"2688565v1.0:3287939v1.0","context":"PS-CC","contextVersion":"1","DataElementConcept":{"publicId":"2688565","version":"1","preferredName":"Stage Prognostic Factor Collaborative Staging Neoplasm Size","preferredDefinition":"Used to record the largest dimension, or the diameter of the primary tumor in millimeters (for example:  1 mm = 001, 1 cm = 010).","longName":"2688190v1.0:2688563v1.0","context":"PS-CC","contextVersion":"1","ObjectClass":{"publicId":"2688190","version":"1","preferredName":"Stage Prognostic Factor","preferredDefinition":"The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.:The general personal and health characteristics that have a bearing on the course of a disease and its eventual outcome.","longName":"C16899:C18959","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prognostic Factor","conceptCode":"C18959","definition":"The general personal and health characteristics that have a bearing on the course of a disease and its eventual outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C0FC8A1-D62E-5124-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-10-09","modifiedBy":"ONEDATA","dateModified":"2007-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2688563","version":"1","preferredName":"Collaborative Staging Neoplasm Size","preferredDefinition":"A coding system for staging of cancer bringing together the principles of Summary Stage, the TNM categories and stage groupings, and the SEER Extent of Disease (EOD) coding structure, creating a carefully selected set of data items that describe how far a cancer has spread at the time of diagnosis. The Collaborative Staging System uses a modified EOD coding system, a five-field, 10 digit system: tumor size (3 digits), extension of the primary tumor (2 digits), regional lymph node involvement (highest specific lymph node chain involved by tumor) (1 digit), the number of pathologically reviewed regional lymph nodes that are positive (2 digits), and the number of pathologically examined regional lymph nodes (2 digits).:(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.:Size; the physical magnitude of something.","longName":"C62575:C3262:C25681","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Collaborative Staging","conceptCode":"C62575","definition":"A coding system for staging of cancer bringing together the principles of Summary Stage, the TNM categories and stage groupings, and the SEER Extent of Disease (EOD) coding structure, creating a carefully selected set of data items that describe how far a cancer has spread at the time of diagnosis. The Collaborative Staging System uses a modified EOD coding system, a five-field, 10 digit system: tumor size (3 digits), extension of the primary tumor (2 digits), regional lymph node involvement (highest specific lymph node chain involved by tumor) (1 digit), the number of pathologically reviewed regional lymph nodes that are positive (2 digits), and the number of pathologically examined regional lymph nodes (2 digits).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Size","conceptCode":"C25681","definition":"The physical magnitude of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C297AF5-27D0-74FB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-10-10","modifiedBy":"ONEDATA","dateModified":"2007-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NAACCR:North American Association of Central Cancer Registries","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C297AF5-27E1-74FB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-10","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-10-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3287939","version":"1","preferredName":"Collaborative Staging Prior To Therapeutic Procedure Neoplasm Size Code","preferredDefinition":"A coding system for staging of cancer bringing together the principles of Summary Stage, the TNM categories and stage groupings, and the SEER Extent of Disease (EOD) coding structure, creating a carefully selected set of data items that describe how far a cancer has spread at the time of diagnosis. The Collaborative Staging System uses a modified EOD coding system, a five-field, 10 digit system: tumor size (3 digits), extension of the primary tumor (2 digits), regional lymph node involvement (highest specific lymph node chain involved by tumor) (1 digit), the number of pathologically reviewed regional lymph nodes that are positive (2 digits), and the number of pathologically examined regional lymph nodes (2 digits)._Earlier in time or order._Used as a function word to indicate direction, purpose, or movement._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Size; the physical magnitude of something._A system of numbered categories for representation of data.","longName":"3287939v1.0","context":"PS-CC","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":"3","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2435030","version":"1","preferredName":"NCI Administrative Concept","preferredDefinition":"Conceptual entities required by NCI operations and systems. Includes administrative, financial, organizational and quasi-scientific concepts required for NCI operations and systems. ","longName":"C28389","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07432182-1611-25E9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3287970","version":"1","preferredName":"Collaborative Staging Prior To Therapeutic Procedure Neoplasm Size Code","preferredDefinition":"A coding system for staging of cancer bringing together the principles of Summary Stage, the TNM categories and stage groupings, and the SEER Extent of Disease (EOD) coding structure, creating a carefully selected set of data items that describe how far a cancer has spread at the time of diagnosis. The Collaborative Staging System uses a modified EOD coding system, a five-field, 10 digit system: tumor size (3 digits), extension of the primary tumor (2 digits), regional lymph node involvement (highest specific lymph node chain involved by tumor) (1 digit), the number of pathologically reviewed regional lymph nodes that are positive (2 digits), and the number of pathologically examined regional lymph nodes (2 digits).:Earlier in time or order.:Used as a function word to indicate direction, purpose, or movement.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:Size; the physical magnitude of something.:A system of numbered categories for representation of data.","longName":"3287970v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Collaborative Staging","conceptCode":"C62575","definition":"A coding system for staging of cancer bringing together the principles of Summary Stage, the TNM categories and stage groupings, and the SEER Extent of Disease (EOD) coding structure, creating a carefully selected set of data items that describe how far a cancer has spread at the time of diagnosis. The Collaborative Staging System uses a modified EOD coding system, a five-field, 10 digit system: tumor size (3 digits), extension of the primary tumor (2 digits), regional lymph node involvement (highest specific lymph node chain involved by tumor) (1 digit), the number of pathologically reviewed regional lymph nodes that are positive (2 digits), and the number of pathologically examined regional lymph nodes (2 digits).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Size","conceptCode":"C25681","definition":"The physical magnitude of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE2D37FC-F65E-89E7-E040-BB89AD437AF7","latestVersionIndicator":"Yes","beginDate":"2011-09-30","endDate":null,"createdBy":"CURTIST","dateCreated":"2011-09-30","modifiedBy":"ONEDATA","dateModified":"2011-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NAACCR:North American Association of Central Cancer Registries","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE2AE29F-0E3C-AC37-E040-BB89AD437465","latestVersionIndicator":"Yes","beginDate":"2010-06-15","endDate":null,"createdBy":"CURTIST","dateCreated":"2011-09-30","modifiedBy":"CURTIST","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2193114","version":"1","longName":"Division of Cancer Control and Population Sciences","context":"PS-CC","ClassificationSchemeItems":[{"publicId":"3134707","version":"1","longName":"NAACCR 12.1","context":"PS-CC"},{"publicId":"3205580","version":"1","longName":"StageProgFactors12.1","context":"PS-CC"}]}],"AlternateNames":[{"name":"2730","type":"NAACCR Item #","context":"PS-CC"},{"name":"CS PRERX TUMOR SIZE","type":"NAACCR Item Name","context":"PS-CC"}],"ReferenceDocuments":[{"name":"Collaborative Staging Pretrea","type":"Preferred Question Text","description":"Collaborative Staging Pretreatment Tumor Size","url":null,"context":"PS-CC"},{"name":"CS Pretreatment Tumor Size Description","type":"DESCRIPTION","description":"This data item belongs to the Collaborative Stage (CS) Data Collection System which is based on the AJCC Cancer Staging Manual, 6th and 7th editions. The CS pre-treatment data items include all information prior to the start of therapy. In rare circumstances where workup could not be completed prior to therapy, these items may be based on testing after limited treatment in the absence of progression or regression of disease, such as delayed planned or usual diagnostic workup. This does not include diagnostic workup for progression of disease or regression. Effective for cases diagnosed 2012+.","url":null,"context":"PS-CC"},{"name":"NAACCR 12.1, Data Stds/Dict.","type":"REFERENCE","description":"For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 12.1 Data Standards and Data Dictionary (6/2010)","url":"http://www.naaccr.org/LinkClick.aspx?fileticket=LJJNRVo4lT4%3d&tabid=133&mid=473","context":"PS-CC"},{"name":"Coding Information","type":"Coding Instructions","description":"See the most current version of the Collaborative Stage Data Collection System (http://cancerstaging.org/cstage/manuals.html), for rules and site-specific codes and coding structures.","url":"http://cancerstaging.org","context":"PS-CC"}],"origin":"NAACCR:North American Association of Central Cancer Registries","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE2CC4A1-8830-0AB3-E040-BB89AD435743","latestVersionIndicator":"Yes","beginDate":"2010-06-15","endDate":null,"createdBy":"CURTIST","dateCreated":"2011-09-30","modifiedBy":"CURTIST","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}